Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Zoom
ZM
|
+$806M |
| 2 |
AbbVie
ABBV
|
+$481M |
| 3 |
T-Mobile US
TMUS
|
+$464M |
| 4 |
Kroger
KR
|
+$430M |
| 5 |
Baidu
BIDU
|
+$423M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$1.35B |
| 2 |
AGN
Allergan plc
AGN
|
+$1.26B |
| 3 |
S
Sprint Corporation
S
|
+$675M |
| 4 |
Amgen
AMGN
|
+$488M |
| 5 |
Humana
HUM
|
+$450M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 23.76% |
| 2 | Technology | 16.41% |
| 3 | Consumer Staples | 10.58% |
| 4 | Consumer Discretionary | 10.13% |
| 5 | Communication Services | 9.97% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2826
Ceco Environmental
CECO
$4.44B
| $566K | ﹤0.01% |
85,898
-28,200
| -25% | -$153K |
|
2827
PJT Partners
PJT
$4.36B
| $565K | ﹤0.01% |
+11,000
| New | +$542K |
|
|
NEOS
2828
DELISTED
Neos Therapeutics, Inc
NEOS
| $564K | ﹤0.01% |
823,143
+121,900
| +17% | +$96.6K |
|
2829
ZK International Group
ZKIN
$62.4M
| $559K | ﹤0.01% |
56,410
-786
| -1% | -$6.64K |
|
|
SHLO
2830
DELISTED
Shiloh Industries Inc
SHLO
| $559K | ﹤0.01% |
345,211
+5,406
| +2% | +$5.99K |
|
2831
China Pharma Holdings
CPHI
$44.2M
| $558K | ﹤0.01% |
1,676
-224
| -12% | -$55.3K |
|
2832
Vanguard Morningstar Mega Cap Growth ETF
MGK
$34B
| $556K | ﹤0.01% |
17,000
-14,500
| -46% | -$433K |
|
|
OPOF
2833
DELISTED
Old Point Financial
OPOF
| $556K | ﹤0.01% |
36,463
+1,122
| +3% | +$17.5K |
|
2834
Babcock & Wilcox
BW
$1.39B
| $554K | ﹤0.01% |
242,888
-63,562
| -21% | -$110K |
|
2835
CubeSmart
CUBE
$9.28B
| $553K | ﹤0.01% |
20,500
-428,211
| -95% | -$11.3M |
|
2836
iShares ESG Aware MSCI USA ETF
ESGU
$18.5B
| $553K | ﹤0.01% |
+7,900
| New | +$520K |
|
|
TTPH
2837
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
| $552K | ﹤0.01% |
219,140
-20,800
| -9% | -$39.4K |
|
|
ALIM
2838
DELISTED
Alimera Sciences
ALIM
| $549K | ﹤0.01% |
87,104
+11,100
| +15% | +$58K |
|
2839
Cogent Biosciences
COGT
$6.47B
| $548K | ﹤0.01% |
297,851
+231,950
| +352% | +$430K |
|
2840
Scully Royalty
SRL
$90.9M
| $548K | ﹤0.01% |
72,170
+6,500
| +10% | +$51.1K |
|
|
LUB
2841
DELISTED
Luby's Inc.
LUB
| $548K | ﹤0.01% |
377,927
+30,800
| +9% | +$30.7K |
|
|
TULP
2842
Bloomia Holdings
TULP
$17.2M
| $546K | ﹤0.01% |
109,198
+600
| +0.6% | +$2.99K |
|
|
MBAI
2843
Check-Cap
MBAI
$9.75M
| $545K | ﹤0.01% |
6,522
+4,305
| +194% | +$381K |
|
|
ORKA
2844
Oruka Therapeutics
ORKA
$7.16B
| $545K | ﹤0.01% |
6,857
-4,251
| -38% | -$278K |
|
|
TCON
2845
DELISTED
TRACON Pharmaceuticals, Inc. Common Stock
TCON
| $544K | ﹤0.01% |
13,870
+2,284
| +20% | +$90.4K |
|
2846
Xtrackers MSCI EAFE Hedged Equity ETF
DBEF
$9.46B
| $541K | ﹤0.01% |
+17,900
| New | +$519K |
|
|
MRIN
2847
DELISTED
Marin Software
MRIN
| $541K | ﹤0.01% |
63,479
+4,586
| +8% | +$40.2K |
|
2848
IZEA Worldwide
IZEA
$53.8M
| $539K | ﹤0.01% |
+118,218
| New | +$331K |
|
2849
Virco
VIRC
$95.5M
| $538K | ﹤0.01% |
205,269
-3,800
| -2% | -$9.38K |
|
|
FRGI
2850
DELISTED
Fiesta Restaurant Group, Inc.
FRGI
| $538K | ﹤0.01% |
84,400
-16,100
| -16% | -$112K |
|
Similar funds
Jim Simons's Q2 2020 Portfolio in Review
As of Q2 2020, Jim Simons held 3,987 positions worth $116B, up 13% from $103B the previous quarter. Its ten largest holdings account for 14% of the portfolio.
Jim Simons withdrew a net $8.24B in Q2 2020, closing 596 positions and reducing 1,366 holdings. Its most notable exit was Allergan plc, an estimated $1.26B position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 24% of assets, down from 26% a quarter earlier, followed by Technology and Consumer Staples.
Against the trend, Jim Simons opened a new position in Uber worth $187M.
- Jim Simons's largest Q2 2020 buy was Uber: 6,030,316 shares worth $187M.
- Jim Simons added most to Zoom in Q2 2020, an estimated $806M increase.
- Jim Simons's biggest Q2 2020 reduction was Bristol-Myers Squibb, cutting an estimated $1.35B.
- Jim Simons fully exited Allergan plc in Q2 2020, selling an estimated $1.26B.
- Jim Simons's ten largest holdings make up 14% of its $116B portfolio in Q2 2020.
- Jim Simons opened 584 new positions and closed 596 in Q2 2020.
- Jim Simons's portfolio value rose 13% quarter-over-quarter to $116B.
Based on Renaissance Technologies's 13F filing for Q2 2020, filed 13 Aug 2020.